MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,493,842
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from the sale of common...
Loss (gain) from change in fair ...
Proceeds from exercise of common...
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-20,319,271
-4,453,081
-23,058,135
-13,292,769
Amortization
13,791
30,417
30,074
29,737
Stock-based compensation
791,670
757,484
881,150
1,820,555
Loss (gain) from change in fair value of promissory notes
1,103,000
-2,495,400
6,743,736
335,581
Warrant inducement expenses (note 10)
-
-
-
-334,940
(gain) loss on extinguishment of debt
-1,329,048
285,600
-
-
Loss (gain) from change in fair value of warrant liability
7,036,009
-6,838,022
2,791,813
-2,682,686
Loss (gain) on equity method investment
-41,012
-45,119
-38,634
-40,419
Accounts receivable
-1,075,537
2,605,219
-1,376,322
-260,491
Inventory
1,699,288
-113,822
119,660
-788,312
Prepaid expenses and other current assets
-1,854,103
2,176,011
439,855
-1,840,783
Other assets
-
-
-
1
Operating lease liabilities
-14,817
-15,238
-13,499
-13,007
Accounts payable
-6,460,902
5,706,232
-2,873,739
30,255
Accrued expenses
-5,760,414
4,387,442
-295,952
354,702
Income taxes payable
-
-
-
-1,554,629
Net cash used in operating activities
-21,010,522
-7,828,055
-14,939,111
-12,377,197
Investment in joint venture
2,100,000
-
-
-
Net cash used in investing activities
-2,100,000
-
-
-
Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs
25,196,142
6,898,857
14,931,536
8,085,009
Payment of issuance costs
1,930,539
-
-
-
Proceeds from exercise of common stock warrants
4,316,371
0
601,914
5,800,040
Proceeds from debt
-
17,000,000
-
0
Repayment of debt
-
17,000,000
-
2,325,581
Payment of financing costs
977,610
-
-
-
Net cash provided by financing activities
26,604,364
6,898,857
15,533,450
11,559,468
Net increase (decrease) in cash and cash equivalents
3,493,842
-929,198
594,339
-817,729
Cash and cash equivalents at beginning of period
8,677,424
8,677,424
8,083,085
14,927,538
Cash and cash equivalents at end of period
11,242,068
7,748,226
8,677,424
8,083,085
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the sale of
common stock and...
$25,196,142
(45.55%↑ Y/Y)
Proceeds from exercise of
common stock warrants
$4,316,371
(-74.35%↓ Y/Y)
Net cash provided by
financing activities
$26,604,364
(-20.41%↓ Y/Y)
Canceled cashflow
$2,908,149
Net increase
(decrease) in cash and cash...
$3,493,842
(157.97%↑ Y/Y)
Canceled cashflow
$23,110,522
Payment of issuance
costs
$1,930,539
Payment of financing
costs
$977,610
Loss (gain) from
change in fair value of...
$7,036,009
(117.44%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,854,103
(69.96%↑ Y/Y)
(gain) loss on
extinguishment of debt
-$1,329,048
Loss (gain) from
change in fair value of...
$1,103,000
(-80.78%↓ Y/Y)
Accounts receivable
-$1,075,537
(-161.41%↓ Y/Y)
Stock-based compensation
$791,670
(-88.81%↓ Y/Y)
Loss (gain) on equity
method investment
-$41,012
(59.23%↑ Y/Y)
Amortization
$13,791
(-84.21%↓ Y/Y)
Net cash used in
operating activities
-$21,010,522
(46.74%↑ Y/Y)
Net cash used in
investing activities
-$2,100,000
Canceled cashflow
$13,244,170
Net loss
-$20,319,271
(58.64%↑ Y/Y)
Accounts payable
-$6,460,902
(-494.97%↓ Y/Y)
Investment in joint venture
$2,100,000
Accrued expenses
-$5,760,414
(-524.97%↓ Y/Y)
Inventory
$1,699,288
(-58.82%↓ Y/Y)
Operating lease
liabilities
-$14,817
(60.09%↑ Y/Y)
Buy us a coffee
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)